The Pfizer-BioNTech COVID-19 vaccine designed to target the Omicron virus variant could be ready for administration as soon as April while Moderna’s COVID-19 vaccine booster designed to neutralize the variant may be ready by August. Trial data on Pfizer-BioNTech jab is on track to be ready for dissemination to regulatory agencies by the end of March but regulators will likely not clear it that month, BioNTech CEO Ugur Sahin told Germany’s Bild newspaper on Feb. 17. The trial started in January. “It depends on the regulatory permission,” Sahin said, adding that the company is in talks with the U.S. Food and Drug Administration and European Union regulators. Clearance could take until the end of May, Sahin said. Moderna’s CEO, Stephane Bancel, meanwhile, told Reuters that the company’s booster shot targeting Omicron could be ready by August. A trial for the booster also started in January. Omicron is a variant of the CCP (Chinese Communist Party) virus that …